import { Pathway } from "@/types/domain";

export const SEED_PATHWAYS: Omit<Pathway, "id">[] = [
  {
    name: "Pseudohypoxia / HIF Pathway",
    slug: "hif-pseudohypoxia",
    description:
      "Succinate accumulation inhibits PHD enzymes, stabilizing HIF-1α and HIF-2α regardless of oxygen levels. This drives angiogenesis (VEGF), metabolic reprogramming (glycolysis shift), and growth factor signaling.",
    upstream_event: "Succinate inhibits PHD1/2/3 (α-KG-dependent dioxygenases)",
    downstream_effects: [
      "HIF-1α/2α stabilization",
      "VEGF upregulation",
      "GLUT1/3 upregulation",
      "Glycolytic enzyme induction",
      "EPO production",
    ],
    druggable: true,
    display_order: 1,
  },
  {
    name: "Epigenetic Dysregulation",
    slug: "epigenetic-dysregulation",
    description:
      "Succinate inhibits TET family DNA demethylases and Jumonji-domain histone demethylases, causing global DNA and histone hypermethylation. This silences tumor suppressors and blocks differentiation.",
    upstream_event:
      "Succinate inhibits TET1/2/3 and KDM histone demethylases",
    downstream_effects: [
      "DNA hypermethylation (CIMP phenotype)",
      "5-hydroxymethylcytosine loss",
      "Tumor suppressor silencing",
      "Histone hypermethylation",
      "Differentiation block",
    ],
    druggable: true,
    display_order: 2,
  },
  {
    name: "VEGF Signaling",
    slug: "vegf-signaling",
    description:
      "Downstream of HIF activation, VEGF/VEGFR2 signaling drives tumor angiogenesis — the formation of new blood vessels that supply the tumor with oxygen and nutrients.",
    upstream_event: "HIF-mediated VEGFA transcriptional activation",
    downstream_effects: [
      "Tumor angiogenesis",
      "Vascular permeability",
      "Endothelial cell proliferation",
      "Tumor blood supply",
    ],
    druggable: true,
    display_order: 3,
  },
  {
    name: "mTOR / PI3K / AKT",
    slug: "mtor-pi3k-akt",
    description:
      "Metabolic reprogramming from SDH loss activates the PI3K/AKT/mTOR signaling axis, promoting cell growth, proliferation, and survival. Multiple upstream inputs converge on mTOR.",
    upstream_event:
      "HIF-mediated growth factor signaling + metabolic stress + AMPK dysregulation",
    downstream_effects: [
      "Cell growth and proliferation",
      "Protein synthesis",
      "Metabolic reprogramming",
      "Survival signaling",
    ],
    druggable: true,
    display_order: 4,
  },
  {
    name: "Glutamine Dependency",
    slug: "glutamine-dependency",
    description:
      "With the TCA cycle disrupted at Complex II, SDH-deficient cells become addicted to glutamine for anaplerosis and lipid synthesis via reductive carboxylation.",
    upstream_event:
      "TCA cycle disruption at succinate → fumarate step",
    downstream_effects: [
      "Glutaminase (GLS) upregulation",
      "Reductive carboxylation for lipid synthesis",
      "α-KG production via glutaminolysis",
      "Metabolic vulnerability",
    ],
    druggable: true,
    display_order: 5,
  },
  {
    name: "Oxidative Stress / ROS",
    slug: "oxidative-stress-ros",
    description:
      "Complex II dysfunction causes electron leak in the electron transport chain, increasing reactive oxygen species (ROS). This drives DNA damage but also creates a therapeutic vulnerability.",
    upstream_event:
      "Impaired electron flow through Complex II → electron leak",
    downstream_effects: [
      "Increased ROS production",
      "Oxidative DNA damage",
      "Genomic instability",
      "PARP activation for DNA repair",
      "Therapeutic vulnerability to further ROS stress",
    ],
    druggable: true,
    display_order: 6,
  },
  {
    name: "Autophagy / Survival",
    slug: "autophagy-survival",
    description:
      "Metabolic stress from SDH loss triggers autophagy as a survival mechanism. Cells rely on autophagy to maintain metabolic homeostasis under energy stress.",
    upstream_event: "Metabolic stress + nutrient sensing dysregulation",
    downstream_effects: [
      "Autophagosome formation",
      "Lysosomal degradation",
      "Metabolic homeostasis maintenance",
      "Survival under stress",
    ],
    druggable: true,
    display_order: 7,
  },
  {
    name: "NAD⁺ Metabolism / NAMPT Axis",
    slug: "nad-metabolism",
    description:
      "SDH loss impairs Complex II of the electron transport chain, causing NADH accumulation and increased mitochondrial ROS. Sustained ROS drives DNA damage that chronically activates PARP1, consuming NAD⁺. Cells compensate by upregulating the NAMPT-mediated NAD⁺ salvage pathway, creating a targetable dependency.",
    upstream_event:
      "Complex II dysfunction → NADH/NAD⁺ imbalance + ROS-driven DNA damage → PARP1 hyperactivation",
    downstream_effects: [
      "Chronic NAD⁺ depletion",
      "PARP-mediated parthanatos vulnerability",
      "Glycolytic NAD⁺ regeneration dependency",
      "NAMPT upregulation as adaptive response",
      "Selective lethality to NAD⁺ biosynthesis inhibition",
    ],
    druggable: true,
    display_order: 8,
  },
  {
    name: "FGFR Signaling (Epigenetic Oncogene Activation)",
    slug: "fgfr-signaling",
    description:
      "In SDH-deficient tumors, genome-wide DNA hypermethylation (CIMP) disrupts CTCF-bound insulator elements across the genome, causing aberrant long-range enhancer–gene contacts. At the FGF3/FGF4 locus, insulator loss induces coordinated overexpression of both ligands, which act in an autocrine loop through FGFR1 to drive proliferation and survival. This epigenetic mechanism of oncogene activation — downstream of succinate accumulation → TET inhibition → CIMP — is distinct from direct receptor mutation and is specifically observed in SDH-deficient (not KIT/PDGFRA-mutant) GIST.",
    upstream_event:
      "Succinate → TET inhibition → DNA hypermethylation (CIMP) → insulator element disruption → FGF3/FGF4 overexpression",
    downstream_effects: [
      "FGF3/FGF4 autocrine secretion",
      "FGFR1 constitutive activation",
      "MEK/ERK and PI3K/AKT proliferative signaling",
      "Resistance to imatinib / KIT-directed therapy",
      "Therapeutic vulnerability to pan-FGFR inhibition",
    ],
    druggable: true,
    display_order: 9,
  },
];
